Related Experiment Videos
Insights
Dapagliflozin helps relax blood vessels and reduces the activation of human vascular endothelial cells, potentially preventing atherosclerosis. This study clarifies a minor typographical error in primer sequences that did not affect the results.
Area of Science:
- Cardiovascular Research
- Endocrinology
- Molecular Biology
Background:
- Atherosclerosis is a chronic inflammatory disease driven by endothelial cell activation.
- Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has shown potential cardiovascular benefits.
- Understanding the molecular mechanisms of dapagliflozin's vascular effects is crucial.
Purpose of the Study:
- To investigate the effects of dapagliflozin on human vascular endothelial cell activation.
- To explore dapagliflozin's role in inducing vasorelaxation.
- To assess the potential of dapagliflozin in inhibiting atherogenesis.
Main Methods:
- Human umbilical vein endothelial cells (HUVECs) were treated with dapagliflozin.
- Cellular activation markers, including nuclear factor-kappa B (NFκB) signaling, were assessed.
- Vasorelaxation assays were performed.
- A typographical error in the NFκB reverse primer sequence was identified and corrected; this correction did not impact experimental validity.
Main Results:
- Dapagliflozin treatment attenuated endothelial cell activation.
- Dapagliflozin induced vasorelaxation in pre-contracted vessels.
- NFκB activation was modulated by dapagliflozin.
Conclusions:
- Dapagliflozin exhibits anti-atherogenic properties by reducing endothelial cell activation and promoting vasorelaxation.
- These vascular effects represent a potential mechanism for dapagliflozin's cardioprotective actions.
- The identified primer sequence correction ensures clarity without compromising study findings.
Abstract:
Gaspari T, Spizzo I, Liu HB, et al. (2018) Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diabetes & Vascular Disease Research 2018; 15(1): 64-73. DOI: 10.1177/1479164117733626 The authors have highlighted a typographical error which exists in the NFκB reverse primer sequence outlined in the paper. The published NFκB reverse primer sequence reads 5'-TGT-CGT-GCT-CCA-CAC-AGC-CAG-GT-3'. The correct sequence for the NFκB reverse primer sequence should read 5'-TGT-CGT-GCT-CCA-CAG-CCA-GGT-3'. The correct NFκB primer sequence was the sequence utilised in production of the NFκB reverse primer used in all PCR experiments undertaken in this study and thus does not impact on the validity of the PCR results.